Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE
- Sponsors Vericel Corporation
- 07 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2014 New trial record